RT Journal Article
SR Electronic
T1 Immunomodulation by intravenous omega-3 fatty acid treatment in older subjects hospitalized for COVID-19: a single-blind randomized controlled trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.27.21268264
DO 10.1101/2021.12.27.21268264
A1 Arnardottir, Hildur
A1 Pawelzik, Sven-Christian
A1 Sarajlic, Philip
A1 Quaranta, Alessandro
A1 Kolmert, Johan
A1 Religa, Dorota
A1 Wheelock, Craig E.
A1 Bäck, Magnus
YR 2021
UL http://medrxiv.org/content/early/2021/12/31/2021.12.27.21268264.abstract
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) with respiratory distress and systemic hyperinflammation. The primary objective of this single-blind randomized controlled proof-of-concept clinical trial was to establish the effects of intravenous (i.v.) omega-3 (n-3) polyunsaturated fatty acid (PUFA) treatment compared to placebo on inflammatory markers in COVID-19, represented by leukocytes as well as inflammatory protein and lipid mediators. Here we also present an exploratory analysis of the mechanisms of action to elucidate the potential to resolve the COVID-19 hyperinflammation through interfering with lipid mediators. Inclusion criteria were COVID-19 diagnosis and clinical status requiring hospitalization. Randomization was 1:1 to a once daily i.v. infusion (2 mL/kg) of either n-3 PUFA emulsion containing 10g of fish oil per 100 mL or placebo (NaCl) for 5 days. Results from 22 older subjects (mean age 81±6.1 years) were analyzed. The neutrophil to lymphocyte ratio was significantly decreased after n-3 PUFA administration. Liquid chromatography–mass spectrometry (LC-MS/MS) -based lipid metabolite analysis established increased proresolving lipid mediator precursor levels and decreased formation of leukotoxin and isoleukotoxin diols by n-3 PUFA treatment. The mechanistic exploration revealed decreased immunothrombosis and preserved interferon-response. Finally, n-3 PUFA treatment may serve to limit cortisone-induced immunosuppression, including preserving leukocyte phagocytic capacity. In conclusion, i.v. n-3 PUFA administration was safe and feasible during hospitalization of multimorbid older subjects for COVID-19. The results identified n-3 PUFA treatment mediated lipid signature of increased proresolving precursor levels and decreased leukotoxin diols in parallel to beneficial immune responses. EudraCT: 2020-002293-28; clinicaltrials.gov: NCT04647604.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04647604Funding StatementThe study received a research grant from King Gustaf V and Queen Victoria Freemason Foundation. The investigators were supported by the Swedish Research Council (Grant number 2019-01486) and the Swedish Heart and Lung Foundation (grant numbers 20180571, 20190625; 20190196; 20200693; 20210519). The sources of funding had no access to the study data and no role in the design, implementation, or reporting.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approved by approved by Swedish Ethical Review Authority (Dnr 2020-02592) and Medical Product Agency (Dnr 5.1-2020-42861).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual participant data that underlie the results reported will be shared, after deidentification, with researchers who provide a methodologically sound proposal. Time Frame: Beginning 9 months following article publication and finishing 36 months following article publication. Access Criteria: Investigators interested in data should contact the corresponding author.